Interview: Pressures On US Generics Industry Go Beyond Current Price Squeeze
Executive Summary
Generics firms in the US must fight back against brand industry attempts to thwart competition as well as regulatory obstacles looming on the horizon, while continuing to grapple with ongoing price erosion, says AAM president and CEO Chip Davis.
You may also be interested in...
Perrigo Rolls Out US ProAir Rival
Perrigo has received US FDA approval for a generic version of Teva’s ProAir albuterol inhaler. The firm is immediately launching a “limited quantity” but is also ramping up production with partner Catalent to meet future demand.
Neuraxpharm Buys Glenmark’s Polish CNS Assets
Neuraxpharm has struck a deal to acquire Glenmark’s CNS portfolio in Poland. As part of the agreement, Glenmark’s Jacek Sawicki has been named as general manager of Neuraxpharm Polska and will lead a business that now incorporates Glenmark’s CNS commercial team.
FDA Overhauls Its Purple Book
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
Need a specific report? 1000+ reports available
Buy Reports